Adjusted profit before tax surged 24% to £74.3 million, driven by broad-based growth
LONDON: Genus plc reported a robust financial performance for the year ended June 30, 2025, with adjusted profit before tax rising 24% to £74.3 million, driven by broad-based growth across its porcine and bovine genetics businesses and strategic progress in China.
Adjusted operating profit including joint ventures climbed 19% to £93.1 million, supported by continued momentum in PIC’s Americas and Asia operations and profitability gains from ABS’s Value Acceleration Programme (VAP).
Statutory profit before tax surged to £28.5 million from £5.5 million, aided by a £3.7 million FDA milestone receipt from Genus’s Chinese partner, Beijing Capital Agribusiness.
Cash generated by operations nearly doubled to £106.2 million, resulting in record free cash inflow of £40.9 million. Basic earnings per share rose 25% to 81.8 pence, while the final dividend was maintained at 21.7 pence per share.
Strategically, Genus secured U.S. FDA approval for its PRRS-resistant pig gene edit and signed agreements to accelerate the formation of a Chinese joint venture with BCA. The JV, 49% owned by Genus, will deliver a gross cash payment of $160 million upon completion and expedite PRP commercialisation in China.
CEO Jorgen Kokke said the company enters FY26 with “increasing confidence,” expecting significant adjusted profit growth in constant currency, in line with market expectations.